Anti-TNF-alpha therapy as a clinical intervention for periprosthetic osteolysis.
Aseptic loosening of total joint arthroplastics due to periprosthetic osteolysis is a frequent cause of implant failure. The absence of clinical interventions to arrest or prevent this complication limits the use of total joint replacement especially in younger patients. Here we review recent studies implicating tumor necrosis factor (TNF)-alpha in periprosthetic osteolysis and the rationale for clinical studies of anti-TNF therapy and other interventions for periprosthetic loosening.
Schwarz
E M
EM
Department of Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA. Edward.Schwarz@URMC.Rochester.edu
Looney
R J
RJ
O'Keefe
R J
RJ
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003577:Cytochrome P-450 Enzyme System / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use; D000068800:Etanercept; D006622:Hip Prosthesis; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D000069285:Infliximab; D006899:Mixed Function Oxygenases / Q000627:therapeutic use*; D010014:Osteolysis / Q000188:drug therapy* / Q000517:prevention & control; D000077268:Pamidronate; D011475:Prosthesis Failure; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D004164:Diphosphonates; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D003577:Cytochrome P-450 Enzyme System; D000069285:Infliximab; D006899:Mixed Function Oxygenases; C035796:antipyrine hydroxylase; D000068800:Etanercept; D000077268:Pamidronate